Last reviewed · How we verify
Placebo (for Sarpogrelate)
Placebo is an inert control substance with no active pharmacological mechanism.
Placebo is an inert control substance with no active pharmacological mechanism. Used for Control arm in Phase 3 trial of Sarpogrelate (active comparator: Sarpogrelate for peripheral arterial disease or thrombotic conditions).
At a glance
| Generic name | Placebo (for Sarpogrelate) |
|---|---|
| Also known as | sugar pill manufactured to mimic sarpogrelate tablet |
| Sponsor | Seoul National University Bundang Hospital |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebo serves as a negative control in clinical trials to establish baseline efficacy and safety profiles against which the active drug (Sarpogrelate) is compared. It contains no active pharmaceutical ingredient and produces therapeutic effects only through psychological mechanisms (placebo effect). In this Phase 3 trial context, placebo allows researchers to isolate the true pharmacological effects of Sarpogrelate from non-specific patient responses.
Approved indications
- Control arm in Phase 3 trial of Sarpogrelate (active comparator: Sarpogrelate for peripheral arterial disease or thrombotic conditions)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Sarpogrelate) CI brief — competitive landscape report
- Placebo (for Sarpogrelate) updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI